Sherri Nash
Primary Care · Fresno, CANPI 1861470759
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 25.7% of the total. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Incyte Corporation$1K
- Sun Pharmaceutical Industries Inc.$801
- LEO Pharma Inc.$687
- Johnson & Johnson$567
- Regeneron Healthcare Solutions, Inc.$447
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,71397%
- Education$2703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $2,305 |
| Incyte Corporation | 32 | $1,286 |
| Sun Pharmaceutical Industries Inc. | 20 | $801 |
| LEO Pharma Inc. | 26 | $687 |
| Johnson & Johnson | 37 | $567 |
| Regeneron Healthcare Solutions, Inc. | 10 | $447 |
| UCB, Inc. | 28 | $427 |
| Surgenex LLC | 25 | $417 |
| Pfizer | 13 | $341 |
| Novartis | 15 | $280 |
| E.r. Squibb & Sons, L.L.C. | 9 | $276 |
| Galderma Laboratories, L.p. | 10 | $233 |
| Lilly USA, LLC | 10 | $199 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $80 |
| Sanofi | 3 | $76 |
| EPI Health, LLC | 3 | $60 |
| Revance Therapeutics, Inc. | 3 | $55 |
| Merz North America, Inc. | 2 | $53 |
| VYNE Pharmaceuticals Inc. | 3 | $53 |
| Amgen | 2 | $50 |
| Botanix SB Inc | 2 | $42 |
| Biofrontera Inc. | 3 | $40 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Avita Medical Americas, LLC | 1 | $27 |
| Nabriva Therapeutics, PLC | 1 | $25 |
| Dermavant Sciences, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Almirall LLC | 1 | $22 |
| Organogenesis Inc. | 1 | $22 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,983 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $78,193 |
| Clobetasol Propionate | 30 | $1,585 |
| Ketoconazole | 51 | $943 |
| Doxycycline Hyclate | 21 | $597 |
| Fluconazole | 67 | $355 |
| Triamcinolone Acetonide | 36 | $330 |
| ValacyclovirValacyclovir Hcl | 13 | $238 |
| Acyclovir | 13 | $141 |
| Doxepin Hcl | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other primary care in Fresno
- Brittney StanleyFresno$14K
- Phaxi YangFresno$8K
- Michelle BergenFresno$4K
- Joan NunooFresno$4K
- Melissa ManriquesFresno$4K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.